ITI Pharma and Healthcare Fund - Regular Plan - Growth Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 08-11-2021
AUM:
₹ 219 Cr
Expense Ratio
2.35%
Benchmark
NIFTY Healthcare TRI.
ISIN
INF00XX01BL5
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
500
Fund Manager
Mr. Dhimant Shah, Mr. Rohan Korde, Mr. Rajesh Bhatia
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| ITI Pharma and Healthcare Fund - Regular Plan - Growth Option | 16.47 | 23.74 | - |
| NIFTY Healthcare TRI | 15.65 | 24.0 | 20.51 |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
16.2886
Last change
-0.01 (-0.0497%)
Fund Size (AUM)
₹ 219 Cr
Performance
14.53% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Fund Manager
Mr. Dhimant Shah, Mr. Rohan Korde, Mr. Rajesh Bhatia
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 15.18 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 9.120000000000001 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.42 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 5.4 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.19 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 4.84 |
| AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 3.93 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 3.91 |
| ASTER DM HEALTHCARE LIMITED EQ | 3.15 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 3.04 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 93.52 |
| Chemicals | 4.57 |
| Information Technology | 1.29 |
| Diversified | 0.32 |
| N/A | 0.3 |